Sarepta stock crashed Friday — wiping out all of its restructuring-tied gains — after a third recipient of one of its gene therapies died.

While the previous two deaths occurred in patients treated with Elevidys, the most recent patient was receiving one of Sarepta's investigational treatments.

According to multiple reports, a 51-year-old man with limb-girdle muscular dystrophy died from acute liver failure after ...

Sarepta Therapeutics Inc. said another patient has died from acute liver failure after receiving one of its gene therapies, putting additional pressure on the biotech company after the recent deaths ...

The Purdy family shares their insights on navigating their child’s rare neurodegenerative disease and their direct ...